4/A: OptimizeRx Executive Stephen Silvestro Corrects Previous Filing on Beneficial Ownership

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, files an amended Form 4 to correct an understatement of beneficially owned shares and an overstatement of shares withheld for tax obligations.

Summary

• Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, filed an amended Form 4 with the SEC.
• The amendment corrects a previous filing from March 6, 2024, regarding changes in beneficial ownership.
• The corrected filing addresses an understatement of previously owned shares and an overstatement of shares withheld for tax obligations.
• On March 1, 2024, Silvestro acquired 1,927 shares of common stock through the vesting of restricted stock units.
• Also on March 1, 2024, 572 shares were withheld by the issuer to satisfy tax obligations at a price of $15.95 per share.
• Following the reported transactions, Silvestro beneficially owns 18,261 shares of OptimizeRx common stock.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting previous errors. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The amended filing corrects previous errors, providing a more accurate representation of the executive's holdings.
• The filing demonstrates transparency and compliance with SEC regulations.

Industry Context

Form 4 filings are standard practice for reporting transactions by company insiders, ensuring transparency in the market.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the US, ensuring transparency of insider transactions.
• Companies like Veeva Systems, Teladoc Health, and GoodRx also have executives who regularly file Form 4s to report changes in their beneficial ownership.

Stakeholder Impact

• The corrected filing ensures that shareholders have accurate information regarding insider ownership.

Key Dates